Pfizer and BioNTech have experienced a mixed bag of fortunes in recent patent disputes with Moderna. In the US, they convinced the US Patent Office to cancel two of Moderna's COVID-19 vaccine patents. Conversely, a series of German courts ruled that Pfizer and BioNTech violated Moderna's COVID-19 vaccine patent, causing setbacks. In other developments, the FDA put BioNTech's malaria vaccine trial on hold but lifted partial clinical hold on a cancer drug study. BioNTech expands its oncology strategy by acquiring Biotheus and reached settlements with the US agency and UPenn over COVID vaccine royalties. They presented positive interim data for investigational B7-H3 Antibody-Drug Conjugate BNT324/DB-1311 in Advanced Solid Tumors at the ESMO Asia Congress. Concerning earnings and stock performance, Clear Street raised BioNTech stock to Buy with a $164 target. Despite this, after announcing a clinical hold on a malaria vaccine trial, the stock fell. Finally, in a clinical trial for pancreatic cancer, the investigational mRNA vaccine demonstrated sustained immune activity.
BIONTECH News Analytics from Tue, 28 May 2024 07:00:00 GMT to Fri, 07 Mar 2025 15:10:48 GMT -
Rating -1
- Innovation 6
- Information 5
- Rumor 3
